미국의 대상포진 백신 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 백신 유형별, 최종 용도별, 부문별 예측(2025-2033년)

U.S. Shingles Vaccine Market Size & Trends:

The U.S. Shingles Vaccine market size was valued at USD 3.41 billion in 2024 and is projected to register a CAGR of 10.17% during 2025 - 2033. Growth in the market is primarily driven by the expanding elderly population, increased awareness of shingles-related complications, and the broader adoption of recombinant vaccine technologies. In preventive healthcare, shingles vaccines are crucial for reducing disease burden among adults aged 50 and above, particularly those with compromised immune function. The introduction of two-dose, adjuvanted formulations has improved long-term efficacy and coverage. In addition, ongoing R&D efforts around mRNA-based shingles vaccines and improved immunization schedules continue to support uptake and market expansion.

The rising need for long-lasting protection in older adults has led to notable improvements in vaccine design, focusing on enhanced immune response and safety. Recombinant vaccines such as Shingrix have shown strong performance in clinical settings. They are widely recommended across the U.S. adult population. Newer vaccine candidates, including mRNA-based formulations, are being developed to offer simpler dosing, broader immune protection, and more efficient production timelines. These innovations are expected to strengthen the market over the coming years, especially as demand for preventive care grows.

Supportive healthcare infrastructure and public health policies also shape the U.S. shingles vaccine landscape. Federal initiatives, adult immunization campaigns, and Medicare coverage for shingles vaccination have improved access and reduced financial barriers for older adults. As the number of immunocompromised individuals rises due to cancer, organ transplants, and chronic conditions, shingles vaccination has become an essential part of clinical guidelines. In response, healthcare systems are expanding outreach, integrating adult vaccines into regular care visits, and aligning with broader public health goals.

Continued investment in R&D and product innovation is further enhancing vaccine availability. Public-private collaborations and funding support are helping accelerate clinical trials and promote the use of advanced technologies like adjuvant systems and mRNA platforms. In addition, real-world studies generate evidence of long-term efficacy, helping drive vaccine confidence and adoption. While Shingrix dominates the current U.S. market, growing global interest in shingles vaccines is reflected in new product approvals elsewhere, such as SKYZoster's approval in Malaysia in 2023. Such developments signal potential for future market expansion and competition.

The growing emphasis on adult vaccination, rising disease burden, and technological progress are expected to sustain strong growth in the U.S. Shingles Vaccine Market. The industry focuses on improving immune response, reducing dosing complexity, and expanding outreach through private and public health channels.

U.S. Shingles Vaccine Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the U.S. Shingles Vaccine market on the product,vaccine type, and end use:

• Product Outlook (Revenue in USD Million, 2021 - 2033)
  • Shingrix
  • Zostavax
  • SKYZoster
• Vaccine Type Outlook (Revenue in USD Million, 2021 - 2033)
  • Recombinant Vaccine
  • Live Attenuated Vaccine
• End Use Outlook (Revenue in USD Million, 2021 - 2033)
  • Private Healthcare Settings
  • Government Healthcare Settings

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Vaccine type
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in U.S.
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Vaccine type outlook
  • 2.2.3. End Use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Shingles Vaccine market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Aging Population & Rising Shingles Incidence
    • 3.2.1.2. Government Programs & Outreach Initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Vaccine Cost & Financial Barriers
    • 3.2.2.2. Vaccine Hesitancy & Logistical Hurdles
• 3.3. U.S. shingles vaccine market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Shingles Vaccine Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Segment Dashboard
• 4.3. U.S. Shingles Vaccine Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. Shingrix
    • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Zostavax
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. SKYZoster
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Shingles Vaccine Market: Vaccine type Estimates & Trend Analysis

• 5.1. Vaccine type Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. U.S. Shingles Vaccine Market by Vaccine type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. Recombinant Vaccine
    • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Live Attenuated Vaccine
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Shingles Vaccine Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. U.S. Shingles Vaccine Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Private Healthcare Settings
    • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
  • 6.4.2. Government Healthcare Settings
    • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. GlaxoSmithKline plc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Pfizer Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Merck & Co., Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. CanSinoBIO
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Vaccitech
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Green Cross Corp
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Geneone Life Science
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. SK Bioscience
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives